Sierra Summit Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Sierra Summit Advisors’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.36M	Buy	+127,550	New	+$1.4M	0.16%	97

Other funds holding FENC

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Hartford Financial Management Hartford, Connecticut $448M AUM 24.02% 1-Year Est. Return

Master's Wealth Management Lancaster, Pennsylvania $343M AUM 11.33% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

PWMG

Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Sierra Summit Advisors's FENC Position: Q3 2026 in Review

Sierra Summit Advisors opened a new position in Fennec Pharmaceuticals (FENC) in Q3 2026: 127,550 shares worth $1.36M. The stake represents 0.16% of the portfolio and ranks #97 among its holdings.

19 funds tracked by Wall St. Rank hold FENC as of Q3 2026.

Sierra Summit Advisors held 127,550 shares of Fennec Pharmaceuticals worth $1.36M as of Q3 2026.
Fennec Pharmaceuticals was a new Sierra Summit Advisors position in Q3 2026.
Fennec Pharmaceuticals made up 0.16% of Sierra Summit Advisors's portfolio in Q3 2026, its #97 holding.
19 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2026.

Based on Sierra Summit Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.